This process involves the release of interferon gamma (IFNγ) from CD8+ T cells, which down-regulates the expression of SLC3A2 and SLC7A11, components of the glutamate-cystine antiporter system xc−, thereby inhibiting cystine uptake by tumor cells and promoting lipid peroxidation and ferroptosis in those cells.14 The gene discussed is CD8A; the disease is neoplasm.